![Heico Breek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Heico Breek
Director Ejecutivo en ACS Biomarker BV .
Perfil
Heico Breek is currently the Chief Executive Officer at ACS Biomarker BV and Encapson BV.
He previously held the position of Chief Executive Officer at Cavadis BV and MirNext BV.
He also worked as the Vice President-Global Marketing at Sanofi-Aventis U.S.
LLC.
Dr. Breek's education includes an MBA and a doctorate from Vrije Universiteit Amsterdam.
Cargos activos de Heico Breek
Empresas | Cargo | Inicio |
---|---|---|
ACS Biomarker BV
![]() ACS Biomarker BV Medical SpecialtiesHealth Technology ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands. | Director Ejecutivo | - |
Encapson BV
![]() Encapson BV Miscellaneous Commercial ServicesCommercial Services Encapson BV operates as a medical device technology company. It specializes in the use of polymer-based capsules for microencapsulation. The company's products include Capsol, a paclitaxol delivery method for drug eluting balloons; and Sono-coat, an echogenic coating that is applied for biopsy and anesthesiology needles, brachytherapy needles, guiding and embryo transfer catheters, and drainage catheters. Encapson was founded by Lee Ayres and Dennis Manuel Vriezema in 2005 and is headquartered in Enschede, the Netherlands. | Director Ejecutivo | - |
Antiguos cargos conocidos de Heico Breek.
Empresas | Cargo | Fin |
---|---|---|
TIGENIX NV | Corporate Officer/Principal | 01/01/2008 |
MirNext BV
![]() MirNext BV BiotechnologyHealth Technology MirNext BV focuses on the discovery, validation and commercialization of microRNAs as novel biomarkers for cardiovascular disease. Its multiple circulating miRNAs act as informative markers for the diagnosis of heart failure, coronary artery disease, and myocardial infarction, as well as used to predict cardiovascular risk, such as mortality and hospitalization. The company was founded in 2012 and is headquartered in Amsterdam, the Netherlands. | Director Ejecutivo | - |
Sanofi-Aventis U.S. LLC
![]() Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Ventas & Marketing | - |
Cavadis BV
![]() Cavadis BV Miscellaneous Commercial ServicesCommercial Services Cavadis BV discovers biomarkers for progression of atherosclerotic disease. The firm’s product series include pipeline, medical need, market potential and personalized medicine. The company was founded in 2007 by Ronald Nanninga and Oscar Schoots and is headquartered in Hilversum, the Netherlands. | Director Ejecutivo | - |
Formación de Heico Breek.
Vrije Universiteit Amsterdam | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 6 |
---|---|
TiGenix NV
![]() TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
Sanofi-Aventis U.S. LLC
![]() Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
Cavadis BV
![]() Cavadis BV Miscellaneous Commercial ServicesCommercial Services Cavadis BV discovers biomarkers for progression of atherosclerotic disease. The firm’s product series include pipeline, medical need, market potential and personalized medicine. The company was founded in 2007 by Ronald Nanninga and Oscar Schoots and is headquartered in Hilversum, the Netherlands. | Commercial Services |
ACS Biomarker BV
![]() ACS Biomarker BV Medical SpecialtiesHealth Technology ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands. | Health Technology |
Encapson BV
![]() Encapson BV Miscellaneous Commercial ServicesCommercial Services Encapson BV operates as a medical device technology company. It specializes in the use of polymer-based capsules for microencapsulation. The company's products include Capsol, a paclitaxol delivery method for drug eluting balloons; and Sono-coat, an echogenic coating that is applied for biopsy and anesthesiology needles, brachytherapy needles, guiding and embryo transfer catheters, and drainage catheters. Encapson was founded by Lee Ayres and Dennis Manuel Vriezema in 2005 and is headquartered in Enschede, the Netherlands. | Commercial Services |
MirNext BV
![]() MirNext BV BiotechnologyHealth Technology MirNext BV focuses on the discovery, validation and commercialization of microRNAs as novel biomarkers for cardiovascular disease. Its multiple circulating miRNAs act as informative markers for the diagnosis of heart failure, coronary artery disease, and myocardial infarction, as well as used to predict cardiovascular risk, such as mortality and hospitalization. The company was founded in 2012 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Heico Breek